- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Myriad Genetics Inc
+ Add to WatchlistMYGN:US
32.2400 USD 0.7700 2.33%As of 20:10:00 ET on 05/22/2013.
Snapshot for Myriad Genetics Inc (MYGN)
| Open: | 33.2800 | Day's Range: | 31.8400 - 33.3600 | Volume: | 1,593,226 |
|---|---|---|---|---|---|
| Previous Close: | 32.2400 | 52wk Range: | 22.0200 - 34.7000 | 1-Yr Rtn: | +26.78% |
Key Statistics for MYGN
| Current P/E Ratio (ttm) | 20.4051 |
|---|---|
| Estimated P/E(06/2013) | 19.2938 |
| Relative P/E vs. SPX | 1.2629 |
| Earnings Per Share (USD) (ttm) | 1.5800 |
| Est. EPS (USD) (06/2013) | 1.6710 |
| Est. PEG Ratio | 1.2113 |
| Market Cap (M USD) | 2,568.07 |
| Shares Outstanding (M) | 79.65 |
| 30 Day Average Volume | 1,336,737 |
| Price/Book (mrq) | 3.9069 |
| Price/Sale (ttm) | 4.6151 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for MYGN
Company Profile & Key Executives for MYGN
Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
| Peter D MeldrumPresident/CEO/Co-Founder | James S EvansCFO/Treasurer |
| Robert Gardner HarrisonChief Information Officer | Jerry S LanchburyChief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
MYGN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page